Fundraising FoxRobin Hood Ventures — 2025 Investments
3 investments dated 2025 · listed companies and verified rows first · show all
Aprea Therapeutics is a biopharmaceutical company developing novel cancer therapies targeting DNA damage response pathways to treat solid tumors including ovarian, colorectal, prostate, and breast cancers.
BiotechDigital HealthMedical DevicesDoylestown, US
John P. Hamill(Executive Officer)inOren Gilad(Chief Executive Officer, President)in
BoardJean-Pierre Bizzari(Director)Gabriela Gruia(Director)Rifat Pamukcu(Director)Bernd Seizinger(Director)
Co-investors5AM VenturesHealthCapRosetta Capital Ltd.Versant VenturesSoleus Capital
FemSelect develops EnPlace, an FDA-cleared, minimally invasive same-day treatment for Pelvic Organ Prolapse in women.
Digital HealthFemTechMedical Devices
Sasha Schrodein
PartnerPitou Devgon· solo GP
Co-investorsMEDA AngelsTransPacific Venture PartnersTriventuresNew Age Ventures
Measure is a social media analytics platform for brand teams managing accounts across markets, agencies, and product lines.
AdTechAI & Machine LearningMarketing TechMedia & EntertainmentSaaSChalfont, US
Thomas Kramer(Executive Officer, Director)
BoardJames Creech(Director)inDan Zitting(Director)
PartnerPitou Devgon· solo GP
Co-investors37 AngelsDelaware Crossing Investor GroupKern Venture Group
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.